Denali(DNLI) - 2025 Q4 - Annual Results

Financial Performance - Denali Therapeutics reported a net loss of $128.5 million for Q4 2025, compared to a net loss of $114.8 million in Q4 2024, and a full-year net loss of $512.5 million, up from $422.8 million in 2024[15]. - Total research and development expenses for Q4 2025 were $97.9 million, slightly down from $99.8 million in Q4 2024, while full-year expenses increased to $418.8 million from $396.4 million in 2024[16]. - General and administrative expenses rose to $39.5 million in Q4 2025 from $30.1 million in Q4 2024, and for the full year, they increased to $136.6 million from $105.4 million[17]. Cash and Assets - Denali has approximately $966.2 million in cash, cash equivalents, and marketable securities as of December 31, 2025[18]. - Total current assets increased to $900,658,000 in December 2025 from $864,436,000 in December 2024, representing a growth of 4.3%[22]. - Cash and cash equivalents rose to $205,326,000, up from $174,960,000, reflecting an increase of 17.4%[22]. - Total assets decreased to $1,144,854,000 from $1,374,180,000, a reduction of 16.7%[22]. Liabilities and Equity - Total liabilities decreased to $131,093,000 in December 2025 from $144,496,000 in December 2024, a reduction of 9.2%[22]. - Total stockholders' equity declined to $1,013,761,000 from $1,229,684,000, a decrease of 17.6%[22]. - Accounts payable decreased to $3,330,000 from $11,137,000, a decline of 70.1%[22]. - Operating lease liability, less current portion, decreased to $27,210,000 from $36,673,000, a reduction of 25.8%[22]. - Long-term marketable securities dropped significantly to $98,322,000 from $359,373,000, a decline of 72.6%[22]. - Finance lease right-of-use asset increased slightly to $48,531,000 from $47,533,000, an increase of 2.1%[22]. - Prepaid expenses and other current assets remained relatively stable, increasing to $32,779,000 from $32,105,000, a growth of 2.1%[22]. Clinical Developments - Denali established commercial readiness for the anticipated launch of tividenofusp alfa for Hunter syndrome, with a PDUFA target action date of April 5, 2026[5]. - The ongoing global Phase 2/3 COMPASS study for tividenofusp alfa is expected to generate confirmatory evidence for global regulatory submissions[5]. - Preliminary Phase 1/2 data for DNL126 in Sanfilippo syndrome type A showed substantial reductions in disease biomarkers, supporting plans for an accelerated approval path[6]. - The company plans to advance four to six additional programs into the clinic over the next three years, focusing on serious neurologic and systemic diseases[4]. - Denali announced a $275 million synthetic royalty funding agreement with Royalty Pharma and a public offering that generated approximately $200 million in net proceeds[13]. - The company is initiating clinical studies for DNL628 in Alzheimer's disease and DNL952 in late-onset Pompe disease, with study start-up activities underway[7].